Related Experiment Video
Updated: Aug 15, 2026
Retroductal Submandibular Gland Instillation and Localized Fractionated Irradiation in a Rat Model of Salivary Hypofunction
Published on: April 24, 2016
223Ra Dichloride Bone-Targeted Therapy in a Case of Metastatic Salivary Duct Carcinoma
Matteo Manfredi1, Mario Airoldi, Marcello Tucci
1From the *Nuclear Medicine Unit, University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin; †Department of Medical Oncology 2, Città della Salute e della Scienza Hospital, Turin; and ‡Division of Medical Oncology, Department of Oncology, University of Turin San Luigi Gonzaga Hospital, Orbassano, Turin, Italy.
Abstract:
Salivary duct carcinoma (SDC) is a rare malignancy, frequently overexpressing androgen receptor (AR). Therefore, similar to AR-positive prostate cancer (PCa), AR-positive SDC patients benefit from androgen deprivation therapy and, after progression on ADT, might take advantage of Ra dichloride, a radiopharmaceutical approved for the treatment of castration-resistant PCa with symptomatic bone disease. We report the case of a 75-year-old man with castration-resistant SDC and osteoblastic bone metastases who, after Ra treatment, achieved adequate control of bone pain and bone lesion reduction with minor side effects. Evaluation of this strategy in other patients with similar characteristics is warranted.
Insights
Radium dichloride shows promise for treating advanced salivary duct carcinoma (SDC) with bone metastases. This radiopharmaceutical effectively managed bone pain and reduced lesions in an androgen receptor-positive SDC patient.
Area of Science:
- Oncology
- Nuclear Medicine
Background:
- Salivary duct carcinoma (SDC) is a rare cancer often expressing androgen receptors (AR).
- AR-positive SDC shares therapeutic vulnerabilities with prostate cancer (PCa), including response to androgen deprivation therapy (ADT).
- Radium dichloride (Ra) is approved for castration-resistant prostate cancer with bone metastases.
Observation:
- A 75-year-old man with castration-resistant SDC and osteoblastic bone metastases was treated with Ra dichloride.
- The patient had previously undergone ADT.
Findings:
- Radium dichloride treatment resulted in effective control of bone pain.
- Significant reduction in bone lesion size was observed.
- The patient experienced only minor side effects.
Implications:
- Radium dichloride may be a viable treatment option for AR-positive SDC patients with bone metastases.
- Further clinical evaluation of this therapeutic strategy in similar patients is warranted.
- This case highlights potential cross-over benefits of PCa therapies in rare salivary gland cancers.
More Related Videos
09:49A Whole Body Dosimetry Protocol for Peptide-Receptor Radionuclide Therapy PRRT: 2D Planar Image and Hybrid 2D+3D SPECT/CT Image Methods
Published on: April 24, 2020
05:40Author Spotlight: Studying Macrophage-Epithelial Cell Interactions in Salivary Gland Regeneration After Injury
Published on: November 17, 2023
